Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jan 19, 2015

166_ip_2015-01-19_0bb7de31-c4ea-4fdd-8b5e-8f77c7a18ee0.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

UniCredit & Kepler Cheuvreux – 14th German Corporate Conference 2015

For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supply Hospital operations Hospital projects and services

i
b
i
2
0
3
G
C
1
N
t
I
t
t
o
p
e
n
c
o
m
e
o
n
o
n
r
u
r
u
2
%
5		 6
%
4		 2
6
%		 3
%

Favorable Industry Dynamics

Aging population and higher incidence of chronic diseases World population age 60+ will more than double by 2050 to >2 bn (OECD)

Increasing health care spending in emerging markets

Increasing health care coverage and per capita spending (e.g. India: US\$59, China: US\$278, vs. USA: US\$8,608; WHO)

Continuing growth of generics

Approx. US\$19 bn branded IV drug sales (base: 2013) go off-patent in the U.S. by 2023

Rise of private providers in health care services

Further privatization of German hospital market Global opportunity to provide dialysis services (e.g. China, India)

Fresenius Group 2013: New Sales and Earnings Records – >1€ bn Net Income One Year Ahead of Plan

Before special items

Fresenius Group: Financial Results

Q
3
/
1
4		 Q
3
/
1
1
4
-
S
l
a
e
s		 G
h
t
o
r
w
c
c
h
l
G
t
t
t
o
a
c
a
a
e
s
r
w
u
r		 €
5
9
7
8
m
,
2
0
%
1
8
%		 €
1
6
7
1
1
m
,
%
1
4
1
1
%
1
E
B
I
T		 h
G
t
o
c
c
r
w
h
l
G
t
t
t
r
o
w
a
c
u
a
r
a
e
s		 €
8
2
0
m
1
0
%
9
%		 €
2
2
2
3
m
,
3
%
1
%
1
i
N
t
e
n
c
o
m
e		 G
h
t
o
r
w
c
c
h
l
G
t
t
t
o
a
c
a
a
e
s
r
w
u
r		 €
2
8
1
m
%
5
%
4		 €
7
6
8
m
%
4
2
%

Before one-time items

Fresenius Group: Financial Results by Business Segment

/
Q
3
1
4		 G
h
t
o
r
w
Q
3
Y
Y
o		 /
Q
1
3
1
4
-		 G
h
t
o
r
w
Q
3
1
Y
Y
o
-
S
l
a
e
s
E
B
I
T		 \$
S
3
U
4
1
1
m
,
\$
U
S
5
9
0
m		 2
%
1
6
%		 \$
S
U
1
1,
5
1
1
m
\$
U
S
1,
5
9
1
m		 %
7
0
%
S
l
a
e
s
E
B
I
T		 €
2
9
1,
4
m
€
2
2
3
m		 6
%
1
%
-		 €
3
6
0
7
m
,
€
6
3
4
m		 0
%
9
%
-
S
l
a
e
s
E
B
I
T		 €
3
6
2
1,
m
€
1
4
7
m		 6
2
%
4
3
%		 €
3
8
8
3
m
,
€
3
9
7
m		 3
%
5
4
1
%
S
l
a
e
s
E
B
I
T		 €
2
5
7
m
€
1
2
m		 0
%
1
2
0
%		 €
6
5
5
m
€
2
7
m		 0
%
8
%

Q3/2014 Business Update

Operations & Markets

North America: FDA status upgrade for U.S. plant

  • Grand Island, N.Y., plant achieved "VAI" status (voluntary action indicated) in Jan 2015 following an Oct 2014 inspection

  • New "VAI" classification permits FDA approval of new products at the plant

Emerging markets: back to double-digit growth

    • China: record quarterly sales (€148 m; 21% organic growth); strong Q4 and approx. 10% organic sales growth in FY14 expected
  • -Latin America: double-digit organic sales growth across all countries

HES sales: stabilized at Q2 level

-€8 m single quarter sales decline yoy

Q3/2014 Business Update

Operations & Markets

l
d
d
H
i
i
i
i
t
t
o
s
p
a
a
m
s
s
o
n
s
p
o
g
e
s
s
n
g
a
s
e
p
e
c
e
r
r
x
d
b
l
h
d
d
d
h
l
2
%
i
i
i
i
i
i
t
t
t
a
m
s
s
o
n
n
c
e
a
s
e
a
e
s
a
s
e
a
n
a
c
q
e
o
s
p
a
s,
r
u
r
-
l
h
l
h
i
i
i
3
5
%
2
0
1
4
i
t
t
t
t
t
n
n
e
o
o
g
a
n
c
s
a
e
s
g
o
a
g
e
w
r
r
w
r
f
h
l
k
h
l
I
i
R
ö
K
i
i
i
t
t
t
n
e
g
a
o
n
o
n
n
m
o
s
p
a
s
r
u
-
d
d
I
i
€
6
0-
8
0
t
t
t
t
n
e
g
a
o
n
c
o
s
e
c
e
o
m
r
r
u
;
-
/
l
/
5
0
5
0
i
2
0
1
4
2
0
1
5
t
a
p
p
o
s
p
r
x.
f
b
f
l
l
f
d
S
i
€
8
5
2
0
1
5
i
n
e
g
e
o
m
p.
o
n
m
e
y
r
s
a.
y
u
y
c
r
-		 ls Hea
Hos
pita
dqu
arte
rs
f
G
h
l
M
j
j
i
i
i
i
t
t
t
a
o
p
o
e
c
n
o
e
m
a
n
n
e
s
o
s
p
a
r
r
w
r
r
u
v
r
y
b
f
d
d
€
1.
7
V
i
t
t
t
t
n
o
n
o
m
e
n
o
n
o
m
p
n
e
c
r
a
c
r
a
a
c
s
r
u
a
r
r
–
-
l
d
/
d
(
)
d
i
i
i
i
j
€
5
2
0
t
t
t
t
n
e
o
n
o
n
m
o
e
n
o
n
p
o
e
m
n
c
u
s
c
s
r
u
c
r
z
a
r
c
a
h
l
3
0
i
i
t
t
t
t
e
n
m
n
g
e
m
e
n
e
e-
o
n
y
r
c
c
a
a
a
s
r
v
c
c
r
a
c
d
l
k
P
j
i
R
i
U
i
t
o
e
e
a
s
n
s
s
a
a
n
e
r
c
y
u
r
,
l
h
L
2
0
1
4
i
i
t
t
t
o
w
e
r
o
r
g
a
n
c
s
a
e
s
g
r
o
w
e
x
p
e
c
a
o
n
s,
-
h
f
d
E
B
I
T
i
i
t
t
t
g
r
o
w
e
x
p
e
c
a
o
n
s
c
o
n
r
m
e

Fresenius Group: 2014 Financial Outlook by Business Segment

O
l
d		 N
e
w
i
F
e
s
e
n
s
r
u
b
i
K
a		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
E
B
I
T
i
m
a
r
g
n		 %
6
%
4
–
1
6
5
%
1
8
%
–		 1
7
%
~
i
F
r
e
s
e
n
u
s
1
l
i
H
e
o
s		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
l
b
d
S
i
i
i
t
t
a
e
s
c
o
n
o
n
a
c
q
e
r
u
u
r
h
l
i
t
o
s
p
a
s
l
h
d
h
l
S
i
i
t
t
a
e
s
g
o
a
c
q
e
o
s
p
a
s
r
w
u
r
i
o
r
g
a
n
c
l
h
h
l
E
B
I
T
H
i
R
ö
i
t
+
e
o
s
n
o
s
p
a
s		 3
%
%
5
–
b
€
1
8
n
~
3
%
5
%
–
€
5
4
0
5
6
0
m
–
i
F
r
e
s
e
n
u
s
d
V
a
m
e		 l
h
S
t
i
a
e
s
g
r
o
w
o
g
a
n
c
r
h
E
B
I
T
t
g
o
r
w		 %
0
%
5
1
–
5
%
1
0
%
–		 0
%
~

1 Before integration costs for acquired hospitals and disposal gains (two HELIOS hospitals; Rhön stake)

Fresenius Group: 2014 Financial Outlook

l
d
O		 f
i
d
C
o
n
r
m
e
h
R
t
e
e
n
e
g
o
v
u
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 1
%
1
6
%
4
‒
1
h
N
i
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
%
%
5
‒

1 Net income attributable to shareholders of Fresenius SE&Co.KGaA before integration costs (Fenwal; acquired Rhön hospitals) and disposal gains (two HELIOS hospitals; Rhön stake)

Guidance includes acquired Rhön hospitals and acquisitions at Fresenius Medical Care

Fresenius Group: Attractive Mid-Term Growth Prospects

Strong and Balanced Health Care Portfolio

Attachments

Fresenius Group: Profit and Loss Statement

h
G
t
r
o
w		 Q
3
Y
Y
o		 h
G
Q
1
3
Y
Y
t
r
o
w
o
-
€
m		 Q
3
/
1
4		 l
t
a
c
u
a
t
a
e
s
r		 t
t
c
o
n
s
a
n
t
a
e
s
r		 Q
3
/
1
1
4
-		 l
t
a
c
u
a
t
a
e
s
r		 t
t
c
o
n
s
a
n
t
a
e
s
r
l
S
a
e
s		 5
9
7
8
,		 1
8
%		 2
0
%		 1
6
7
1
1
,		 1
1
%		 1
4
%
1
E
B
I
T		 8
2
0		 9
%		 0
%
1		 2
2
2
3
,		 %
1		 3
%
N
i
t
t
t
e
n
e
e
s
r		 1
4
8
-		 9
%
-		 1
0
%
-		 4
3
1
-		 4
%		 1
%
I
t
n
c
o
m
e
a
x
e
s		 1
9
7
-		 1
4
%
-		 1
6
%
-		 5
2
9
-		 7
%
-		 1
0
%
-
2
N
i
t
e
n
o
m
e
c		 2
8
1		 %
4		 %
5		 6
8
7		 2
%		 %
4

1 2014 before integration costs (Fenwal – Q3: €3 m / Q1-3: €6 m; acquired Rhön hospitals – Q3: €4 m / Q1-3: €12 m) and disposal gains (two HELIOS hospitals – Q3: n.a. / Q1-3: €22 m; Rhön Stake – Q3: n.a. / Q1-3: €35 m); 2013 before integration costs (Fenwal – Q3: €7 m; Q1-3: €34 m)

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs (Fenwal Q3: €2 m / Q1-3: €4 m; acquired Rhön hospitals Q3: €3 m / Q1-3: €9 m) and disposal gains (two HELIOS hospitals – Q3: n.a. / Q1-3: €21 m; Rhön Stake – Q3: n.a. / Q1-3: €34 m); 2013 before integration costs (Fenwal – Q3: €6 m; Q1-3: €26 m)

Fresenius Kabi: Organic Sales Growth Accelerating

€
m		 Q
3
/
1
4		 O
i
r
g
a
n
c
h
G
t
r
o
w
Q
3
Y
Y
o		 Q
3
/
1
1
4
-		 O
i
r
g
a
n
c
h
G
t
r
o
w
Q
1
3
Y
Y
o
-
f
h
I
i
T
n
s
o
n
e
a
p
u
r
y		 2
8
4		 3
%		 2
7
4		 2
%
I.
V
D
r
u
g
s		 4
4
4		 3
%		 3
2
1
1
,		 2
%
C
l
l
i
i
N
i
i
t
t
n
o
n
c
a
u
r		 3
8
5		 9
%		 0
2
0
1
,		 6
%
d
l
/
i
i
M
D
e
c
a
e
c
e
s
v
f
h
l
T
i
T
n
o
n
e
n
o
o
g
r
a
s
u
s
c
y		 2
4
4		 %
4		 0
7
4		 3
%
l
l
T
t
o
a
s
a
e
s		 2
9
1
4
,		 %
5		 3
6
0
7
,		 3
%

Fresenius Kabi: Organic Sales Growth Accelerating

€
m		 /
Q
3
1
4		 i
O
g
a
n
c
r
G
h
t
o
r
w
Q
3
Y
Y
o		 /
Q
1
3
1
4
-		 i
O
g
a
n
c
r
G
h
t
o
r
w
Q
3
1
Y
Y
o
-
E
o
p
e
u
r		 5
1
4		 4
%		 1
5
3
8
,		 2
%
h
N
A
i
t
o
r
m
e
r
c
a		 3
7
1		 1
%
-		 1
1
1
8
,		 0
%
f
A
i
P
i
i
s
a
a
c
c
-		 2
9
5		 9
%		 2
3
7		 7
%
/
f
L
i
A
i
A
i
t
n
m
e
a
r
c
a
r
c
a		 0
1
5		 %
1
7		 3
8
1		 3
%
1
l
l
T
t
o
a
s
a
e
s		 2
9
1
4
,		 %
5		 3
6
0
7
,		 3
%

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€
m		 Q
3
/
1
4		 h
G
t
o
r
w
Q
3
Y
Y
o		 Q
3
/
1
1
4
-		 h
G
t
o
r
w
Q
3
1
Y
Y
o
-
E
o
p
e
u
r
M
i
a
r
g
n		 7
7
1
5.
0
%		 0
%
b
-6
0
p
s		 2
2
7
1
4
8
%		 1
1
%
-
b
-1
9
0
p
s
h
i
N
t
A
o
m
e
c
a
r
r
M
i
a
r
g
n		 1
3
3
3
5.
8
%		 %
4
-
-1
4
0
b
p
s		 1
9
4
3
7.
5
%		 3
%
-
4
0
b
p
s
f
/
/
f
A
i
P
i
i
L
i
A
i
A
i
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
M
i
a
r
g
n		 2
7
6
%
1
7.		 2
0
%
0
b
7
p
s		 8
0
1
6.
3
%
1		 0
%
0
b
-7
p
s
d
C
C
R
&
D
t
t
o
p
o
a
e
a
n
o
p
o
a
e
r
r
r
r		 5
9
-		 1
8
%
-		 1
9
2
-		 1
3
%
-
l
T
t
E
B
I
T
o
a		 2
2
3		 %
1
-		 6
3
4		 9
%
-
M
i
a
r
g
n		 2
%
1
7.		 %
1
c
c
-1
3
0
b
p
s		 6.
9
%
1		 -6
%
c
c
-1
7
0
b
p
s

EBIT excluding integration costs (Fenwal – Q3: €3million / Q1-3: €6 million)

Fresenius Helios: Sales and EBIT Growth Driven by First-Time Consolidation of Rhön Hospitals

€
m		 /
Q
3
1
4		 h
G
t
r
o
w
Q
3
Y
Y
o		 /
Q
1
3
1
4
-		 h
G
t
r
o
w
Q
1
3
Y
Y
o
-
l
l
T
t
o
a
s
a
e
s		 3
6
2
1
,		 6
2
%		 3
8
8
3
,		 3
%
5
E
B
I
T
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
r
g
n		 0
3
1
8
%
1
1.		 3
%
0
b
-4
p
s		 2
8
7
%
1
1.
1		 %
4
0
b
p
s
/
A
i
i
i
D
i
i
t
t
t
c
q
u
s
o
n
s
v
e
s
u
r
e
s		 4
4		 0
1
1
(
l
d
/
d
l
d
)
i
i
i
i
1
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r
M
i
a
g
n
r		 8.
9
%		 8.
5
%
l
T
t
E
B
I
T
o
a		 1
4
7		 4
3
%		 3
9
7		 4
1
%
i
M
a
g
n
r		 1
0
8
%		 b
-1
4
0
p
s		 1
0
2
%		 b
-9
0
p
s

Before integration costs (acquired Rhön hospitals: €12 million) and disposal gains (two HELIOS hospitals: €22 million; Rhön stake: €35 million)

Fresenius Helios: Performance Indicators

Q
3
/
1
1
4
-		 Q
3
/
3
1
1
-		 h
C
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
1
1
8
7
2
4		 7
4
5
1
2
3		 5
0
%
%
7
1
%
4
1
f
b
d
N
o
o
e
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 3
4
2
7
6
,
2
9,
0
1
7
0
6
5,
1		 2
3
5
0
2
,
8,
8
8
1
5
6
4,
1
7		 4
6
%
%
5
4
%
1
1
d
A
i
i
m
s
s
o
n
s
(
)
A
t
i
t
i
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 8
0,
5
7
7
5		 6
8,
3
0
5
7		 0
%
5
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 8
%
4		 8
%
4
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 6.
6
2
6.
6		 6.
6
2
6.
8

December 31, 2013

Page 19 UniCredit & Kepler Cheuvreux - 14th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 19, 2015

Fresenius Helios: 2013 Clinic Development Plan

i
f
l
i
Y
P
t
e
a
r
s
n
o
r
o
o
1
<		 1 2 3 4 5 6 6
>		 l
T
t
o
a
N
f
l
i
i
o.
o
c
n
c
s		 - 1
2		 3 1 - 6 4 4
8		 7
4
(
€
)
R
e
v
e
n
u
e
m		 - 3
9
0		 1
5
5		 3
8		 - 9
6
1		 3
2
1		 2,
9
8
1		 3,
2
8
9
T
t
a
r
g
e
E
B
I
T
i
(
%
)
m
a
r
g
n		 - 2.
0		 4
0		 6.
0		 8.
0		 1
0.
0		 1
2.
0		 1
2.
0-
1
5.
0
(
)
E
B
I
T
€
m		 - 7.
8		 6.
2		 2.
3		 - 1
9
6		 3
7.
4		 2
6
3.
8		 3
3
7.
1
d
R
t
e
p
o
r
e
(
)
E
B
I
T
i
%
m
a
g
n
r		 - 1
1.
4		 0.
5		 3.
4		 - 7.
5		 1
2.
8		 1
3.
0		 1
1.
8
(
)
E
B
I
T
€
m		 - 4
4
6		 0.
8		 1.
3		 - 1
4
7		 3
9
9		 2
8
5.
9		 3
8
7.
2
f
l
N
i
i
t
t
>
o.
o
c
n
c
s
a
g
e
r		 - 9 1 - - 2 2 1
7		 3
1
f
l
N
i
i
t
t
<
o.
o
c
n
c
s
a
g
e
r
IFR
S		 - 3 2 1 - 4 2 3
1		 4
3

Page 20 UniCredit & Kepler Cheuvreux - 14th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 19, 2015

Fresenius Vamed: Sales and EBIT in Line with Expectations

€
m		 /
Q
3
1
4		 G
h
t
r
o
w
Q
3
Y
Y
o		 /
Q
1
3
1
4
-		 G
h
t
r
o
w
Q
3
1
Y
Y
o
-
b
P
j
i
t
o
e
c
s
n
e
s
s
r
u
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 1
3
3
1
2
4		 7
%
1
4
%		 3
0
6
3
4
9		 8
%
-
8
%
l
l
T
t
o
a
s
a
e
s		 2
5
7		 1
0
%		 6
5
5		 0
%
l
T
E
B
I
T
t
o
a
M
i
a
r
g
n		 2
1
4
7
%		 2
0
%
4
0
b
p
s		 2
7
4
1
%		 8
%
3
0
b
p
s
1
O
d
k
i
t
r
e
r
n
a
e
1
O
d
b
k
l
r
e
r
a
c
o
g		 3
8
7		 n
a		 6
8
7
0
1
5
4
,		 8
%
7
2
3
2
%

Project business only

2December 31, 2013

Consistent Cash Generation and Proven Track Record of Deleveraging

Cash Flow Development LTM

€
m		 i
O
C
F
t
p
e
r
a
n
g		 (
)
C
t
a
p
e
x
n
e		 1
h
l
F
C
F
r
e
e
a
s
o
w
Q
3
/
L
T
M
1-
1
4		 i
L
T
M
M
a
r
g
n		 Q
3
/
L
T
M
1-
1
4		 i
L
T
M
M
a
r
g
n		 Q
3
/
L
T
M
1-
1
4		 i
L
T
M
M
a
r
g
n
6
1
7		 2
3
%
1		 3
4
5
-		 6
9
%
-		 2
2
7		 %
5
4
4
7
6		 1
0
0
%		 2
2
9
-		 4
8
%
-		 2
4
7		 3
5
2
%
0 0
%		 9
-		 0
9
%
-		 9
-		 0
9
%
-
Co
/
te
rp
or
a
O
he
t
r		 8
1
-		 n
a		 9
-		 n
a		 2
7
-		 n
a
l.
F
M
C
ex
c		 1
0
7
5
,		 2
1
0
7
%		 5
9
2
-		 5
5
%
-		 4
8
3		 2
5
2
%
G
ro
up		 2
9
4
4
,		 %
1
1
1		 2
3
6
1
-
,		 6
%
5
-		 2
3
1
1
,		 %
5
5

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 6.6% excluding €66 million of capex commitments from acquisitions

Page 23 UniCredit & Kepler Cheuvreux - 14th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 19, 2015

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

1Before integration costs (Fenwal; acquired Rhön hospitals) and disposal gains (two HELIOS hospitals; Rhön stake)

2Pro forma including Rhön hospitals, Sound Inpatient Physicians, Inc. and excluding two HELIOS hospitals

4Before integration costs (Fenwal: €6 million; acquired Rhön hospitals: €12 million) and disposal gains (two HELIOS hospitals: €22 million; Rhön stake: €35 million); 2013 before integration costs (Fenwal: €54 million)

Page 24 UniCredit & Kepler Cheuvreux - 14th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 19, 2015

32013 before integration costs (Fenwal: €54 million); pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG (€2.18 bn)

Share Information

Share key facts

Number of shares1 541,389,079 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

As of October 31, 2014

Financial Calendar 2015

2
0
2
2
0
5
1
5		 2
0
R
F
Y
1
4
t
e
p
o
o
n
r
3
0
0
2
0
4
1
5		 t
Q
2
0
R
1
1
5
t
t
s
e
p
o
o
n
a
e
r
u
r
r
2
0
0
2
0
5
1
5		 f
l
G
l
k
/
A
M
i
F
M
i
t
t
n
n
a
e
n
e
a
e
e
n
g
a
n
a
n
u
r
r
u
r
,
3
0
0
2
0
7
1
5		 d
2
2
0
R
1
5
t
t
n
e
p
o
o
n
q
e
r
u
a
r
r
2
9
0
2
0
1
1
5		 d
3
2
0
R
1
5
t
t
r
e
p
o
o
n
q
e
r
u
a
r
r

Please note that these dates could be subject to change.

Contact

d
B
i
i
G
t
g
n
r
r
u		 l
S
V
P
I
R
i
F
i
S
E
&
C
K
G
A
t
t
n
e
s
o
e
a
o
n
s
e
s
e
n
s
o
a
v
r
r
u
l
h
T
e
e
p
o
n
e
:
l
i
e
-m
a
:		 4
9
6
1
7
2
6
0
8
2
4
8
5
+
-
d
f
B
i
i
G
@
i
t.
r
g
r
u
n
r
e
s
e
n
u
s
c
o
m

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.